Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the FoF Domestic median (127 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Gold history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Invesco India Gold ETF Fund of Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹96.82 |
| 12 Apr 2015 | ₹83.27 |
| 31 May 2016 | ₹87.78 |
| 19 Jul 2017 | ₹83.55 |
| 07 Sep 2018 | ₹92.14 |
| 27 Oct 2019 | ₹113.07 |
| 15 Dec 2020 | ₹144.64 |
| 03 Feb 2022 | ₹141.00 |
| 25 Mar 2023 | ₹172.95 |
| 12 May 2024 | ₹209.99 |
| 01 Jul 2025 | ₹272.76 |
| 20 Aug 2026 | ₹431.02 |
| Metric | Invesco · Direct · IDCW NAV ₹45.16 High risk ★★★☆☆ | Category median FoF Domestic · 127 funds |
|---|---|---|
| +55.96% | +6.09% | |
| +36.60% | +11.54% | |
| +25.34% | +7.95% | |
| +16.08% | +9.85% | |
| +11.32% | +8.39% | |
| +32.25% | — | |
| +11.21% | +11.20% | |
| +10.84% | +9.48% | |
| +10.75% | +10.18% | |
| Risk | ||
| 25.16% | 12.96% | |
| 1.20 | 0.43 | |
| 1.75 | 0.62 | |
| -33.40% | -17.91% | |
| Gold | — | |
| -0.46% | +0.56% | |
| 1.00 | 0.95 | |
| 97.8% | 95.5% | |
| 95.5% | 86.6% | |
| 0.11% | 0.14% | |
| ₹483.23Cr | ₹338.76Cr | |
| 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹1.00K | — | |
| — | 14% | |
| Abhisek Bahinipati · 0.8y | — | |
| 02 Jan 2013 | — | |
| — | — | |
| — | — | |
| 2.3% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.